Carfilzomib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Drug reference
darbepoetin alfa
Erythropoiesis-Stimulating Agent · Hematopoietic Agent
Erythropoiesis-Stimulating AgentHematopoietic Agent
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
4 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 5 →
- CarfilzomibSevereDatabaseDDInter
- LenalidomideSevereDatabaseDDInter
- PomalidomideSevereDatabaseDDInter
- ThalidomideSevereDatabaseDDInter
Mechanism
Darbepoetin alfa is an engineered epoetin that displays a longer circulatory half-life compared to other epoetins. It stimulates red blood cell production by binding to erythropoietin receptors on erythroid progenitor cells, promoting their proliferation and maturation.
Indications
anemia associated with chronic kidney diseaseanemia associated with cancer chemotherapy
Dosing
- Adult
- Chronic Kidney Disease: 0.45 μg/kg administered intravenously or subcutaneously once weekly or 0.75 μg/kg administered every 2 weeks. Dose adjustments depend on response, with a rise of less than 1 g/dL every 2 weeks generally considered safe.
Contraindications
- pre-existing uncontrolled hypertension
Side effects
Common
headachetachycardiaedemashortness of breathnauseavomitingdiarrheainjection site stingingflu-like symptoms (arthralgias, myalgias)
Serious
- thrombotic events
- cancer recurrence (in cancer patients)
- decreased on-study survival (in cancer patients)
- hypertensive encephalopathy
- seizures
- death (if administered to target hemoglobin concentrations near normal physiological levels)
Drug interactions
Lenalidomide
Severe
Database
.
Source: DDInter
Pomalidomide
Severe
Database
Clinical effect not specified
Source: DDInter
Thalidomide
Severe
Database
.
Source: DDInter
Anticoagulants
Moderate
Textbook
During hemodialysis, patients receiving darbepoetin alfa may require increased anticoagulation.
Patients during hemodialysis may require increased anticoagulation. Monitoring for thrombotic events is recommended.
Source: G&G 14e · p902
7 additional unreviewed or low-confidence interactions hidden because their provenance or source detail is insufficient.
Related guidelines
Other Erythropoiesis-Stimulating Agent drugs
Ask House about darbepoetin alfa
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: Goodman & Gilman 14e·Updated: 2026-05-10